WW International (NASDAQ:WW), otherwise known as Weight Watchers, reported encouraging second quarter results and full year guidance following the company’s emergence from bankruptcy last month which left the company with $1.15B less in debt.
The company identified two periods for Q2: a “predecessor” period from March 30 to June 24, 2025, and the “successor” period from June 25 to June 30, 2025.
Total revenue for the combined period of $189M was down 6% from the previous year on headwinds to the Behavioral business. But thanks to the popularity of weight loss drugs, the total revenue from the Clinical unit increased 55% year-over-year to $31M. Beginning May 22, the Clinical business began transitioning subscribers from compounded semaglutide to FDA-approved medications.
At the end of the combined period, WW International (NASDAQ:WW) had 3.2M total subscribers.
Predecessor adjusted EBITDA totaled $61M, while successor adjusted EBITDA totaled $4M. This resulted in an adjusted EBITDA margin of 34% and 37%, respectively.
“With greater flexibility to invest, we’re accelerating innovation across our platform to meet the evolving needs of our members,” said WW International CEO Tara Comonte. “Our integrated model, spanning clinical care, behavioral support, and community, puts us in a powerful position to reinforce our leadership in long-term weight health.”
For FY25, WW International (NASDAQ:WW) expects total revenue to be between $685M and $700M versus $699.97M estimates, while adjusted EBITDA is targeted for $140M to $150M.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.